TY - JOUR
T1 - Bone turnover markers after sleep restriction and circadian disruption
T2 - A mechanism for sleep-related bone loss in humans
AU - Swanson, Christine M.
AU - Shea, Steven A.
AU - Wolfe, Pamela
AU - Cain, Sean W.
AU - Munch, Mirjam
AU - Vujović, Nina
AU - Czeisler, Charles A.
AU - Buxton, Orfeu M.
AU - Orwoll, Eric S.
N1 - Funding Information:
Financial Support: Research reported in this manuscript was supported by grants from the Medical Research Foundation of Oregon Early Clinical Investigator Grant MRF515 (to C.M.S), the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000128 (to E.S.O.), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR070275 to C.M.S.), National Institutes of Health (NIH) (T32 DK007674 and T32 DK007446 to C.M.S), and the National Institute on Aging [P01 AG009975 to C.A.C. (PI), O.M.B. (Project Leader)]. The studies were carried out in the Intensive Physiological Monitoring Unit of the Brigham and Women’s Hospital Center for Clinical Investigation, part of the Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, UL1 TR0001102 and UL1 RR025758), and financial contributions were provided by Harvard University and its affiliated academic health care centers and with support from the Joslin Diabetes and Endocrinology Research Center Service (5P30 DK 36836) Specialized Assay Core. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Disclosure Summary: In the interest of full disclosure, we report the following; however, we do not believe any of these pertain to the current work. C.M.S., P.W., S.W.C., and M.M. have nothing to declare. S.A.S. received support from NASA (grant NNX1OAR1OG), Centers for Disease Control and Prevention (grant U19 OH010154), and NIH (grant R01 HL125893). N.V. is supported by the following NIH grants: F32AG051325, R01DK099512, R01HL118601, and R01DK105072. C.A.C. is a consultant to Amazon.com, A2Z Development Center, Bose, Boston Celtics, Boston Red Sox, Cleveland Browns, Columbia River Bar Pilots, Institute of Digital Media and Child Development, Jazz Pharma, Merck, NBA Coaches Association, Purdue Pharma, Quest Diagnostics, Samsung, Teva, Vanda Pharma; holds equity in Vanda Pharma; receives research/education support from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, NFL Charities, Jazz Pharma, Optum, ResMed, San Francisco Bar Pilots, Schneider, Simmons, Sysco, Philips, and Vanda; is an expert witness in legal cases, including those involving Bombardier, Continental Airlines, FedEx, Greyhound, Purdue Pharma, and UPS; serves as the incumbent of a professorship endowed by Cephalon; and receives royalties from McGraw Hill, Houghton Miflin Harcourt, and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. C.A.C.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. O.M.B. previously served as consultant to Takeda Pharmaceuticals North America (speaker’s bureau), Dinsmore LLC (expert witness testimony), Matsutani America (scientific advisory board), and Chevron (speaking fees); received unrelated investigator-initiated research grant support from Sepracor (now Sunovion) and Cephalon (now Teva); and was supported in part by the National Heart, Lung, and Blood Institute (R01HL107240). Outside of the current work, O.M.B. received two subcontract grants to Pennsylvania State University from Mobilesleeptechnologies (NSF/STTR #1622766, NIH/NIA SBIR R43AG056250). E.S.O. has received research support from Lilly and Merck. E.S.O. as overall PI for the Osteoporotic Fractures in Men (MrOS) Study is supported by NIH funding via the following institutes: the National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Advancing Translational Sciences, and NIH
Funding Information:
Research reported in this manuscript was supported by grants from the Medical Research Foundation of Oregon Early Clinical Investigator Grant MRF515 (to C.M.S), the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000128 (to E.S.O.), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR070275 to C.M.S.), National Institutes of Health (NIH) (T32 DK007674 and T32 DK007446 to C.M.S), and the National Institute on Aging [P01 AG009975 to C.A.C. (PI), O.M.B. (Project Leader)]. The studies were carried out in the Intensive Physiological Monitoring Unit of the Brigham and Women’s Hospital Center for Clinical Investigation, part of the Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, UL1 TR0001102 and UL1 RR025758), and financial contributions were provided by Harvard University and its affiliated academic health care centers and with support from the Joslin Diabetes and Endocrinology Research Center Service (5P30 DK 36836) Specialized Assay Core. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
Copyright © 2017 Endocrine Society.
PY - 2017/10
Y1 - 2017/10
N2 - Context: Sleep abnormalities are associated with low bone mineral density. Underlying mechanisms are unknown. Objective: Investigate the impact of sleep restriction with circadian disruption on bone biomarkers. Design: Intervention study. Participants and Methods: Four bone biomarkers [C-terminal cross-linked telopeptide of type I collagen (CTX) = bone resorption, N-terminal propeptide of type I procollagen (P1NP) = bone formation, sclerostin and fibroblast growth factor 23 = osteocyte function] were measured in bihourly serum samples over 24 hours at baseline and after;3 weeks of sleep restriction (5.6 hours sleep/24 hours) with concurrent circadian disruption (recurring 28-hour “day” in dim light) in 10 men (age groups: 20 to 27 years, n = 6; 55 to 65 years, n = 4). The effects of sleep/circadian disruption and age on bone biomarker levels were evaluated using maximum likelihood estimation in a mixed model for repeated measures. Results: P1NP levels were lower after intervention compared with baseline (P, 0.001); the decrease in P1NP was greater for younger compared with older men (28.0% vs 18.2%, P, 0.001). There was no change in CTX (D = 0.03 6 0.02 ng/mL, P = 0.10). Sclerostin levels were higher postintervention in the younger men only (D = 22.9% or 5.64 6 1.10 pmol/L, P, 0.001). Conclusions: These data suggest that 3 weeks of circadian disruption with concurrent sleep restriction can lead to an uncoupling of bone turnover wherein bone formation is decreased but bone resorption is unchanged. Circadian disruption and sleep restriction may be most detrimental to bone in early adulthood.
AB - Context: Sleep abnormalities are associated with low bone mineral density. Underlying mechanisms are unknown. Objective: Investigate the impact of sleep restriction with circadian disruption on bone biomarkers. Design: Intervention study. Participants and Methods: Four bone biomarkers [C-terminal cross-linked telopeptide of type I collagen (CTX) = bone resorption, N-terminal propeptide of type I procollagen (P1NP) = bone formation, sclerostin and fibroblast growth factor 23 = osteocyte function] were measured in bihourly serum samples over 24 hours at baseline and after;3 weeks of sleep restriction (5.6 hours sleep/24 hours) with concurrent circadian disruption (recurring 28-hour “day” in dim light) in 10 men (age groups: 20 to 27 years, n = 6; 55 to 65 years, n = 4). The effects of sleep/circadian disruption and age on bone biomarker levels were evaluated using maximum likelihood estimation in a mixed model for repeated measures. Results: P1NP levels were lower after intervention compared with baseline (P, 0.001); the decrease in P1NP was greater for younger compared with older men (28.0% vs 18.2%, P, 0.001). There was no change in CTX (D = 0.03 6 0.02 ng/mL, P = 0.10). Sclerostin levels were higher postintervention in the younger men only (D = 22.9% or 5.64 6 1.10 pmol/L, P, 0.001). Conclusions: These data suggest that 3 weeks of circadian disruption with concurrent sleep restriction can lead to an uncoupling of bone turnover wherein bone formation is decreased but bone resorption is unchanged. Circadian disruption and sleep restriction may be most detrimental to bone in early adulthood.
UR - http://www.scopus.com/inward/record.url?scp=85031312067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031312067&partnerID=8YFLogxK
U2 - 10.1210/jc.2017-01147
DO - 10.1210/jc.2017-01147
M3 - Article
C2 - 28973223
AN - SCOPUS:85031312067
SN - 0021-972X
VL - 102
SP - 3722
EP - 3730
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 10
ER -